medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 4

<< Back Next >>

Ann Hepatol 2016; 15 (4)

Elevated circulating levels of IL-21 and IL-22 define a cytokine signature profile in type 2 autoimmune hepatitis patients

Thomas-Dupont P, Remes-Troche JM, Izaguirre-Hernández IY, Sánchez-Vargas LA, Maldonado-Rentería MJ, Hernández-Flores KG, Torre A, Bravo-Sarmiento E, Vivanco-Cid H

Language: English
References: 35
Page: 550-558
PDF size: 593.62 Kb.


ABSTRACT

Background and aims. Autoimmune hepatitis (AIH) is a chronic inflammatory condition of the liver in which the immunological mechanisms involved in tissue destruction and/or repair are still unclear. Different pro-inflammatory cytokines have been shown to play a determinant role in AIH pathogenesis. Here, we aim to compare the circulating levels of pro- and anti-inflammatory cytokines such as IL-6, TNF-α, IL-17A/F, IL-21, IL-22, IL-23, and IL-10 in patients with type 2 AIH compared to patients with type 1 AIH and healthy controls (HC). Fourty-six Mexican patients with AIH were recruited in our study. Patients were classified as type 1 or 2 AIH based on immune serological markers. Fourty-four serum samples from healthy individuals were included as controls. Serum cytokine levels were determined by ELISA technique. Results. Compared to healthy controls, serum levels of IL-17F, IL-21, IL-23, IL-10, IL-6, and TNF-α, but not IL-17A and IL-22, were significantly increased in AIH patients. When patients were grouped by aminotransferase activity, a biomarker of active disease, a positive correlation between serum IL-17F and alanine transaminase (rs: 0.4739; P = 0.0009) and aspartate transaminase (rs: 0.4984; P = 0.0004) levels was found. A cytokine signature profile associated with type 2 AIH was characterized by high serum IL-21 (type 1 AIH: 0.66 pg/mL; type 2 AIH: 331.1 pg/mL; P = 0.0042) and IL-22 (type 1 AIH: 0.1 pg/mL; type 2 AIH: 55.26 pg/mL; P = 0.0028) levels. Conclusions. We show for the first time, differential regulation of certain pro-inflammatory cytokines associated with disease progression and AIH type in Mexican patients.


REFERENCES

  1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.

  2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.

  3. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009; 31: 421-35.

  4. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.

  5. Beland K, Lapierre P, Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol 2009; 15: 1025-34.

  6. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 1995; 20: 23-7.

  7. Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Meyer zum Buschenfelde KH. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994; 14: 161-6.

  8. Bayer EM, Herr W, Kanzler S, Waldmann C, Meyer Zum Büschenfelde KH, Dienes HP, Lohse AW. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998; 28: 803-11.

  9. Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, Qiu D, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011; 6:e18909.

  10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.

  11. Coss E, Granados J, Uribe M, Torre A. Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis type 1? Ann Hepatol 2011;10: 28-32.

  12. Lisker R, Ramirez E, Briceno RP, Granados J, Babinsky V. Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol 1990; 62: 791-801.

  13. Qian C1, Jiang T, Zhang W, Ren C, Wang Q, Qin Q, Chen J, et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine 2013; 64: 172-80.

  14. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181: 8-18.

  15. Kamijo A, Yoshizawa K, Joshita S, Yoneda S, Umemura T, Ichijo T, Matsumoto A, et al. Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients. Hepatol Res 2011; 41: 350-7.

  16. Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation 2001; 71:229-33.

  17. Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68: 1275-81.

  18. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49: 128-40.

  19. Maranville JC, Baxter SS, Torres JM, Di Rienzo A. Inter-ethnic differences in lymphocyte sensitivity to glucocorticoids reflect variation in transcriptional response. Pharmacogenomics J 2013; 13: 121-9.

  20. Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol 2010; 7: 250-4.

  21. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 2013; 191: 1835-44.

  22. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2: e60.

  23. Distler JH, Jüngel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, et al. Expression of interleukin- 21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52: 856-64.

  24. Jüngel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA et al. Expression of interleukin- 21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1468-76.

  25. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55: 1774-80.

  26. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008; 112: 4940-7.

  27. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, Dong C, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010; 71: 334-41.

  28. Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC, Kallenberg CG, Bijl M. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R157.

  29. van Leeuwen MA, Lindenbergh-Kortleve DJ, Raatgeep HC, de Ruiter LF, de Krijger RR, Groeneweg M, Escher JC, et al. Increased production of interleukin-21, but not interleukin- 17A, in the small intestine characterizes pediatric celiac disease. Mucosal Immunol 2013; 6: 1202-13.

  30. Pan Q, Yu Y, Tang Z, Xi M, Jiang H, Xun Y, Liu X, et al. Increased levels of IL-21 responses are associated with the severity of liver injury in patients with chronic active hepatitis B. J Viral Hepat 2014; 21: e78-e88.

  31. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118: 597-607.

  32. Pan HF, Li XP, Zheng SG, Ye DQ. Emerging role of interleukin- 22 in autoimmune diseases. Cytokine Growth Factor Rev 2013; 24:51-7.

  33. Marijnissen RJ, Koenders MI, Smeets RL, Stappers MH, Nickerson- Nutter C, Joosten LA, Boots AM, et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum 2011; 63: 2939-48.

  34. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 2011; 23: 159-63.

  35. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 2014; 59: 1331-42.




2020     |     www.medigraphic.com